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Antiviral compounds targeting cellular metabolism instead of virus components have 
become an interesting issue for preventing and controlling the spread of virus infection, 
either as sole treatment or as a complement of vaccination. Some of these compounds 
are involved in the control of lipid metabolism and/or membrane rearrangements. Here, 
we describe the effect of three of these cell-targeting antivirals: lauryl gallate (LG), valproic 
acid (VPA), and cerulenin (CRL) in the multiplication of viruses causing important porcine 
diseases. The results confirm the antiviral action in cultured cells of LG against African 
swine fever virus (ASFV), foot and mouth disease virus (FMDV), vesicular stomatitis virus 
(VSV), and swine vesicular disease virus (SVDV), as well as the inhibitory effect of VPA 
and CRL on ASFV infection. Other gallate esters have been also assayed for their inhibition 
of FMDV growth. The combined action of these antivirals has been also tested in ASFV 
infections, with some synergistic effects when LG and VPA were co-administered. 
Regarding the mode of action of the antivirals, experiments on the effect of the time of 
its addition in infected cell cultures indicated that the inhibition by VPA and CRL occurred 
at early times after ASFV infection, while LG inhibited a late step in FMDV infection. In all 
the cases, the presence of the antiviral reduced or abolished the induction of virus-specific 
proteins. Interestingly, LG also reduced mortality and FMDV load in a mouse model. The 
possible use of cell-targeted antivirals against porcine diseases is discussed.
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INTRODUCTION
Conventional antiviral drugs (AVs) that interfere with viral proteins or functions have been 
developed against a number of different animal viral diseases, but these compounds often lead 
to selection of drug resistance in virus populations evolving under selective pressures (Cuypers 
et  al., 2016; Maldonado and Mansky, 2018). An alternative approach is the identification of 
compounds targeted against cellular functions required for viruses to complete their multiplication 
cycle. Hence, an efficient non-conventional cell-targeted antiviral would inhibit viral entry and/
or replication at a non-toxic concentration for the cell and, ideally, it would help to control 
a wide variety of viral diseases and virus strains. Following this approach, we  have focused 
our studies on three compounds: lauryl gallate (LG), valproic acid (VPA), and cerulenin (CRL) 
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(Table 1) that can interfere with cell metabolism and have 
been previously described as potential AVs.
LG is an ester derivative of gallic acid, a natural plant 
phenolic compound. It has been widely used as antioxidant 
(E312) in food manufacturing, as well as in the pharmaceutical 
and cosmetic industries. LG protects cells from oxidative stress, 
in a process associated with radical scavenging, inhibition of 
enzymes involved in lipid peroxidation, and increasing expression 
of antioxidant genes (Kubo et al., 2002). Due to its hydrophobic 
properties, LG can disrupt biomembranes and cause protein 
inactivation (Jurak and Minones, 2016). This interaction with 
lipid molecules can be correlated with different pharmacological 
effects against bacterial cells and viruses (Ogita et  al., 2004; 
Hurtado et  al., 2008). We  have previously demonstrated that 
viral production was strongly inhibited at non-toxic 
concentrations of LG, in different cell lines infected with African 
swine fever virus (ASFV), herpes simplex virus (HSV-1), vaccinia 
virus (VV), influenza virus, transmissible gastroenteritis virus 
and Sindbis virus (Hurtado et  al., 2008).
VPA is a branched short-chain fatty acid that has been 
widely used for treatment of neurological diseases such as 
epilepsy, migraines, or bipolar disorders (Terbach and Williams, 
2009). VPA has been shown to alter a variety of signaling 
pathways, including an increase in GABA neurotransmission, 
inhibition of histone deacetylases (HDACs), inhibition of glycogen 
synthase kinase beta (GSK3β), or attenuation of phospholipid 
signaling (Terbach and Williams, 2009). Therapeutic roles of 
VPA have been proposed in cancer, Alzheimer’s disease, and 
HIV treatment (Monti et  al., 2010). We  previously showed 
that VPA is a potent inhibitor of the multiplication of several 
enveloped viruses (Vazquez-Calvo et  al., 2011). VPA treatment 
of vesicular stomatitis virus (VSV)-infected cells reduced viral 
production without significantly affecting viral RNA and protein 
synthesis but interfering with both cell release and specific 
infectivity of virion particles, while VPA blocked virus entry 
and multiplication during West Nile virus (WNV) (Vazquez-
Calvo et al., 2013) and HSV-1 infection (Crespillo et al., 2016).
The FASN synthase inhibitor cerulenin has been shown to 
reduce production of several viruses such as VV, WNV, and 
Semliki Forest virus (Martin-Acebes et  al., 2011; Greseth and 
Traktman, 2014; Royle et  al., 2017), suggesting that de novo 
fatty acid biosynthesis is relevant for numerous viral infections.
Despite the considerable effort invested in new vaccine 
designs, viruses still produce many porcine diseases with 
economic importance, such as those caused by ASFV, foot 
and mouth disease virus (FMDV), VSV, or swine vesicular 
disease virus (SVDV), and many aspects regarding 
their spread and persistence remain elusive. ASFV causes an 
important animal disease for which no effective vaccine or 
therapeutic treatment is available (Sanchez-Cordon et al., 2018). 
Likewise, FMD is the animal viral disease with 
the largest economic impact worldwide. Conventional 
vaccines have allowed FMD control and eventual eradication 
of the disease when properly produced and administered, but 
pose shortcomings such as the need of high-containment 
facilities for production, short-lived immunity, and 
short shelf-life after formulation (Sobrino et al., 2001). A limited 
repertoire of antiviral drugs is available for ASFV and FMDV 
and those targeting cell host factors are extracts of several 
plants, marine microalgae, stilbenes, and other organisms 
(Fabregas et  al., 1999; Galindo et  al., 2011; Mottola et  al., 
2013; Hakobyan et  al., 2016; De Vleeschauwer et  al., 2017). 
There is a current trend to consider antiviral 
compounds as a valuable complement to vaccination for the 
efficient short-term control of animal viruses such as FMDV.
MATERIALS AND METHODS
Cells and Viruses
Vero and COS (both from African green monkey kidney), 
BHK21 (baby hamster kidney), and IBRS-2 (pig kidney) 
cells were grown at 37°C in DMEM medium supplemented 
with 5 or 10% fetal calf serum. ASFV isolates, either from 
a field strain (E70) or a Vero cell-adapted strain (Ba71V), 
were grown in swine alveolar macrophages (E70) or in Vero 
cells and titrated on COS cell monolayers, as described 
(Carrascosa et al., 2011). Type C FMDV C-S8 isolate (Sobrino 
et  al., 1983) and VSV Indiana (Novella et  al., 1996) virus 
stocks were grown in BHK21 cells, while type O FMDV 
0-UKG 11/2001 (The Pirbright Institute, UK) and SVDV 
SP93 (Borrego et  al., 2002) viral stocks were produced in 
IBRS-2 cells.
Virus Infection and Antiviral Treatment
Cell monolayers were grown on multiwell plates and incubated 
for 1  h with different AVs (purchased from Sigma). Stock 
solutions of LG, VPA, and CRL were prepared in DMEM 
(VPA) or 2% ethanol (a concentration previously shown to 
preserve more than 80% cell viability) and diluted in DMEM 
to prepare the working stocks. After 1  h of incubation with 
AVs, duplicate cultures were infected with the corresponding 
virus in a reduced volume of medium containing the AV, for 
1–2  h; the virus inoculum removed and cells washed twice 
with medium, before the addition of drug-containing fresh 
medium (supplemented with 2% FCS). Cultures were then 
TABLE 1 | Formula and cytotoxicity of antivirals in different cell lines.
Antivirala
Cell line LG VPA CRL
Vero 45 μM 50 mM 45 μM
COS 33 μM 180 mM 60 μM
BHK 75 μM 175 mM 60 μM
IBRS-2 30 μM 40 μM
aData expressed as CC50, concentration of antiviral yielding a 50% of cell viability in 
MTT assay.
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incubated until massive cytopathic effect was observed. Total 
virus (intracellular and extracellular) production was evaluated 
by plaque assay on the corresponding virus-sensitive cells. From 
the dose-effect relationship of each AV on each virus yield, 
50% inhibitory concentrations (IC50) were determined.
Cell Viability Assay
Cell viability determinations were performed by the MTT assay, 
as described (Hurtado et  al., 2008). Briefly, cell monolayers 
were grown on 96-well plates before the addition of the AV 
(six wells for each dose). After 24  h of incubation, 
MTT-containing culture medium was added and cells were 
incubated for 2 h and lysed with SDS-containing lysis solution. 
Absorbance at 550 nm was determined after 15 min of incubation, 
and average values (from six wells) obtained were subtracted 
from the background levels (in the absence of cells) and 
compared with the data scored in the absence of drug (100% 
viability). CC50 values (concentration of AV yielding a 50% of 
cell viability) shown in Table 1 were determined from the 
viability curves of each cell line with each AV (Figures 1, 2).
Direct Virucidal Effect
To determine a possible direct virucidal effect of the AVs on 
virus particles, suspensions of either ASFV or FMDV (105 pfu) 
in 0.9  ml of culture medium were incubated with 0.1  ml of 
LG, VPA, or CRL solutions (from 0 to 300  μM for LG and 
CRL, or 0 to 300 mM for VPA); controls with viruses incubated 
in 2% ethanol in the absence of the drug were included. After 
1  h of incubation at room temperature, samples were diluted 
(1:1000) and titrated by plaque assay on virus-sensitive cell 
monolayers (COS for ASFV and BHK for FMDV samples). 
Virus titers were compared in duplicate samples with those 
obtained in virus samples incubated in the absence of the 
drug (Figure 3).
FIGURE 1 | Inhibition of ASFV production by different AVs. Vero or COS cell monolayers were incubated for 1 h with LG (0–40 μM), VPA (0–50 mM), or CRL 
(0–50 μM) and then infected with ASFV Ba71V or E70 strains, in medium containing the same AV concentration. Total virus produced at 24 h.p.i. was titrated by 
plaque assay on Vero or COS cell monolayers in duplicate samples and represented as virus yield (%). The viability of non-infected Vero or COS cells incubated in 
the same conditions, assayed by MTT, is also represented as cell viability (%).
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FIGURE 2 | Inhibition of vesicular porcine viruses production by LG. BHK21 or IBRS-2 cell monolayers were incubated for 1 h with LG (0–40 μM) and then infected 
with FMDV C-S8 or O-UK isolates, VSV Indiana strain or SVDV SP93 isolate in medium containing the same LG concentrations. Total virus produced at 24 h.p.i. 
was titrated by plaque assay on BHK21 (for FMDV C-S8 and VSV) or IBRS-2 (for FMDV O-UK and SVDV) cell monolayers in duplicate samples, and represented as 
relative virus yield (%). The viability of non-infected BHK21 or IBRS-2 cells incubated in the same conditions, assayed by MTT, is also represented as cell viability (%).
FIGURE 3 | LG, CRL, and VPA virotoxicity on FMDV or ASFV. Virus suspensions were incubated for 1 h at room temperature with LG, VPA, or CRL (from 0 to 
300 μM for LG and CRL, or 0 to 300 mM for VPA); controls with viruses incubated in 2% ethanol in the absence of the drug were included (vehicle). At each AV 
concentration, total virus was titrated by plaque assay.
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Time of Addition Assay
To address the step in the virus cycle targeted by each AV, 
susceptible cell monolayers (Vero for ASFV or BHK and IBRS2 
for FMDV) were infected with virus at a M.O.I. of 2 (ASFV) 
or 0.1, 1, or 5 (FMDV) pfu/cell. After adsorption, the inoculum 
was removed and cells were further incubated. At different times 
(from 3  h before infection to 24  h after infection), AVs were 
added to duplicate wells at the selected inhibitory concentration 
(10  μM LG, 20  mM VPA, or 25  μM CRL), and the cultures 
were further incubated until 24 h post-infection (h.p.i.), collected, 
and the total virus productivity evaluated by plaque assay.
Virus-Specific Protein Expression
Vero cells were pre-treated before virus infection with 20  mM 
VPA or 25  μM CRL for 1  h and then infected with the ASFV 
isolate Ba71V (M.O.I. of 2 pfu/cell) in the presence of the AV. 
Virus inoculum was removed and cells were further incubated 
with the AV in fresh medium. At 0, 4, and 24 h.p.i., cell cultures 
were collected and lysed in TNT buffer (20  mM Tris–HCl pH 
7.5, 0.2  M NaCl, 1% Triton X100) supplemented with protease 
inhibitor cocktail tablets (Roche). Total intracellular proteins 
(20–30 μg) were separated by 12% polyacrylamide gel electrophoresis 
and electroblotted. After incubation with rabbit antiserum specific 
for ASFV proteins induced late in the infection, membranes were 
exposed to horseradish peroxidase-conjugated antirabbit antibody 
(Amersham) and revealed by ECL autoradiography.
In the case of FMDV-specific proteins, BHK21 cells were 
pre-treated with 10  μM LG for 1  h and infected with C-S8 
isolate (M.O.I. of 1 pfu/cell) in the presence of 10  μM LG as 
indicated above. Cell extracts were collected and the blotted 
proteins incubated with MABs SD6 or 2D2 (specific for VP1 
and 3C FMDV proteins, respectively) (Garcia-Briones et al., 2006), 
and revealed as above.
Extraction of Foot and Mouth Disease 
Virus RNA and RT-qPCR
BHK21 cells were pre-treated with LG for 1  h and infected 
with FMDV C-S8 isolate (M.O.I. of 1 pfu/cell) in the presence 
of 10 μM LG. Virus inoculum was removed and infected cultures 
were further incubated with LG in fresh medium. At 0, 1, 2, 
3, and 8  h.p.i, cultures were collected and total (intracellular 
and extracellular) RNA was extracted using Tri-Reagent (Sigma). 
cDNA was synthesized using SuperScript III reverse transcriptase 
(Invitrogen), and qPCR was performed using LightCycler FastStart 
DNA Master SYBR Green I  (Roche) containing 10  pmol each 
of forward and reverse primers that amplified a conserved 290-bp 
region in the 3D gene (Saiz et al., 2003). The qPCR was performed 
on a LightCycler 2.0 instrument. The number of FMDV RNA 
copies (VRC) was inferred from a standard curve prepared using 
10-fold dilutions of cDNA from plasmid PMT28 encoding the 
genomic FMDV RNA (Garcia-Arriaza et  al., 2004).
“In vivo” Model for Foot and Mouth 
Disease Virus Inhibition by Lauryl Gallate
LG was initially dissolved in DMSO and then diluted in 
Tween80: ethanol: saline (1:1:8). Groups of 6–12 
8-week-old C57 (B16J) female mice were inoculated 
intraperitoneally (i.p.) as described (Baranowski et al., 2003) 
with different concentrations of LG and administration 
schedules. Mice were challenged i.p. with 103 or 104 pfu/
mouse of type C FMDV C-S8 and monitored daily for 
signs of infection up to 4  days p.i. Control mice were 
inoculated with the same volume of PBS alone plus vehicle. 
Mice exhibiting clear signs of disease, as well as all surviving 
mice at the end of the experiment, were anesthetized 
and euthanized.
To determine viral load after LG treatment, three animals 
per group were bled and euthanized at day 2 p.i. for further 
RNA extraction from blood, spleen, lung, heart, and thymus 
samples, using Tri-Reagent (Sigma) and RT-qPCR was performed 
as described above.
Statistical Analysis
Data handling and analysis were performed using Graph Prism 
6.01 software. Statistical differences were determined using a 
Student’s t test (p  <  0.05).
RESULTS AND DISCUSSION
Direct Virotoxicity of Antiviral Drugs on 
African Swine Fever Virus and Foot and 
Mouth Disease Virus
Direct virucidal effect of the AVs selected for this study in 
ASFV or FMDV infections was assayed by incubation of virus 
samples for 1  h at room temperature with increasing 
concentrations (from 0 to 300  μM for LG and CRL, or 0 to 
300  mM for VPA) of the drugs. As shown in Figure 3, no 
direct toxicity was observed in ASFV or FMDV samples when 
incubated with the compounds in the range of 
concentrations analyzed.
Inhibition of African Swine Fever Virus by 
Different Antiviral Drugs
We assessed the inhibitory effect of VPA and CRL on ASFV 
infection. ASFV inhibitor LG (Hurtado et al., 2008) was included 
in these experiments for comparative purposes. We first assayed 
the cytotoxicity of LG, VPA, and CRL in different cell lines. 
Cultures of Vero, COS, BHK21, or IBRS-2 cells were incubated 
for 24  h in the presence of increasing concentrations of the 
AVs and the CC50 values were determined (Table 1). The 
concentrations selected to determine the potential inhibition 
exerted by these compounds were: 1–20  μM LG, 5–30  mM 
VPA, and 10–50  μM CRL. Virus yield was reduced about 3 
log.u. when Vero (IC50: 1  μM) or COS (IC50: 0.4  μM) cell 
monolayers were infected with the non-pathogenic ASFV isolate 
Ba71V in the presence of LG (Figure 1), as expected from 
previous results (Hurtado et  al., 2008). A similar reduction of 
ASFV production was observed in the presence of non-toxic 
concentrations of VPA (IC50: 2.5–3  mM), and of CRL (IC50: 
9  μM). Moreover, the virulent ASFV isolate E70 was also 
inhibited in COS cells infected in the presence of similar 
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concentrations of the three drugs (IC50: 2  μM for LG, 2.5  mM 
for VPA, and 3  μM for CRL).
To confirm the antiviral effect of CRL and VPA in ASFV 
infection, we analyzed the expression of virus proteins induced 
in Vero cells at late times of infection (Figure 4A). No late 
ASFV proteins (like p17 or p12) and a very low expression 
of the early virus protein p32 were detected in cultures infected 
in the presence of CRL or VPA, as reported in LG-treated 
ASFV-infected Vero cells (Hurtado et  al., 2008). This decrease 
in protein synthesis was consistent with the inhibition observed 
in infective virus yield. The low levels of p32 detected, mainly 
at late times (24  h.p.i), are likely due to the accumulation of 
residual virus particles less sensitive to the AVs. Late ASFV 
protein P72 could not be quantified because of its co-migration 
with similar molecular weight-unspecific proteins, even detectable 
in mock samples.
We next studied the effect of the time of addition of the 
AVs on virus yield, assuming that assessing the step in virus 
cycle targeted by the drug may reveal information on the 
mechanism of action of the AV. As shown in Figure 4B, ASFV 
infection was greatly reduced when the AVs were added prior 
to virus adsorption. In the case of CRL, recovery of virus 
productivity was observed when CRL was added as early as 
0  h after infection (simultaneous with the virus inoculum), 
which could support its implication in preventing virus 
attachment. Nevertheless, it has been described that CRL, among 
other inhibitors of cholesterol synthesis, affected ASFV production 
in Vero cells by inhibiting a fusion activity, without affecting 
the binding and internalization of the virus particles (Bernardes 
et  al., 1998). While in that work, the inhibitor was added 
simultaneously to the virus, in our experiment, CRL was present 
3 h before infection, allowing a possible effect of this compound 
on the cell membranes before virus adsorption.
On the other hand, the addition of VPA in successive times 
from 0 to 8 h.p.i. resulted in a gradual recovery of virus yields, 
and even a second infective step was noticed after 15  h.p.i.
Combined administration of different inhibitors is one of 
the strategies being currently explored to improve antiviral 
treatments (De Vleeschauwer et  al., 2017). We  studied the 
effect on ASFV infection of LG, VPA, and CRL, either alone 
or, searching for possible synergistic effects, in their possible 
combinations but most of the mixtures of two AVs resulted 
in an inhibitory effect similar to that obtained with the single 
drugs, or at least not higher than the sum of effects of both AVs. 
A
B
FIGURE 4 | (A) Effect of VPA and CRL on ASFV protein expression. Vero cells were preincubated or not with 20 mM VPA or 25 μM CRL and infected with ASFV 
Ba71V strain at a M.O.I of 2 pfu/cell. Non-adsorbed virus was washed away and the cultures maintained in the presence or absence of the AV to complete the virus 
cycle. Cell extracts obtained at different h.p.i. were subjected to western blot analysis to detect early (P32) or late (P17 and P12) ASFV-induced proteins in the 
presence or absence of the AV. ASFV-induced proteins are indicated by arrows. Molecular weight markers are shown (MW) in the left lane. Graphs show the relative 
quantification of bands corresponding to P32, P17, and P12 proteins versus actin expression control. Statistically significant differences between control and AV-
treated cells are indicated by asterisks (Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001). (B) Effect of time of addition of VPA or CRL on their inhibitory activity. 
Vero cells were infected with ASFV Ba71V strain at a M.O.I. of 2 pfu/cell, and 20 mM VPA or 25 μM CRL was added at different times before or after infection, 
maintaining the presence of the AV up to the completion of virus cycle (24 h.p.i.) when total virus was titrated on Vero cell monolayers. Time 0 h.p.i. represents the 
end of virus adsorption (-2 to 0 h.p.i.). Dotted lines indicate the total virus production in the absence of inhibitor, corresponding to the value at 24 h.p.i.
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Nevertheless, in a few cases, combination of LG and VPA 
resulted in a slightly higher inhibitory effect than that expected 
from the sum of their individual effects (data not shown).
Inhibition of Vesicular Porcine Viruses by 
Lauryl Gallate
We next analyzed the effect of LG in cells infected by different 
vesicular porcine viruses: FMDV, VSV, and SVDV. VPA was 
not included in this study since, as we  previously reported, 
VSV is susceptible to this drug while FMDV and SVDV 
infections are not affected (Vazquez-Calvo et  al., 2011). As 
shown in Figure 2, a consistent decrease of at least 1 log.u. 
in the production of both FMDV isolates from serotypes C 
(C-S8) and O (0-UKG 11/2001, named O-UK) in BHK21 or 
IBRS-2 cells at different M.O.I.s was observed in the presence 
of 10  μM LG (IC50: 0.2–2.5  μM at M.O.Is of 0.01–1 for C-S8; 
IC50: 0.7  μM at M.O.I of 1 for O-UK). In the case of cells 
infected with VSV or SVDV, the presence of LG reduced the 
virus productivity by 2 or 1 log.u., respectively (IC50: 0.9  μM 
for VSV; IC50: 1.7  μM for SVDV).
Characterization of the Inhibition Exerted 
by Lauryl Gallate on Foot and Mouth 
Disease Virus Infection
We further characterized the effect of LG on FMDV infection, 
as the availability of cost-effective antivirals for this virus, that 
A B
C
FIGURE 5 | Inhibition exerted by LG on FMDV infection. (A) Protein expression. BHK21 cell monolayers were preincubated or not with 10 μM LG and infected with 
FMDV C-S8 isolate at a M.O.I of 2 pfu/cell. Non-adsorbed virus was washed away and the cultures maintained in the presence or absence of LG for 4 h. Cell 
extracts obtained at different h.p.i. were subjected to western blot analysis to detect FMDV structural (VP1) and non-structural (3C) proteins. FMDV-induced proteins 
are indicated by arrows. Molecular weight markers are shown (MW) in the left lane. Graphs show relative quantification of bands corresponding to VP1 and 3C 
proteins versus α-tubulin expression control. (B) RNA quantification. BHK21 cells were preincubated or not with 10 μM LG and infected with FMDV C-S8 isolate at a 
M.O.I of 2 pfu/cell. Non-adsorbed virus was washed away and the cultures maintained in the presence or absence of LG for 8 h. Total viral RNA (intracellular and 
extracellular) was extracted at different times p.i. and amplified by RT-qPCR. Data are expressed as VRC (number of viral RNA copies)/ml of total or extracellular 
virus. Detection limit was 104 VRC/ml. (C) Effect of time of addition of LG on its inhibitory activity. Vero cells were infected with FMDV C-S8 isolate at a M.O.I. of 0.1 
pfu/cell (low M.O.I.) or 1 or 5 pfu/cell (high M.O.I.), and 10 μM LG was added at different times before or after infection, maintaining the presence of LG up to 
24 h.p.i. when total virus was titrated on BHK21 cell monolayers. Time 0 h.p.i. represents the end of virus adsorption (-2 to 0 h.p.i.). Statistically significant 
differences between control and LG-treated cells are indicated by asterisks (Student’s t-test, *p < 0.05, ***p < 0.001, ****p < 0.0001).
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severely impacts global livestock security, is limited (De 
Vleeschauwer et  al., 2017). To determine the effect of LG on 
FMDV protein synthesis, the expression of structural (VP1) 
and non-structural (3C) FMDV proteins was analyzed at different 
times after virus infection in the presence or absence of the 
AV. As expected, the expression of both proteins was significantly 
reduced (Figure 5A), which is consistent with the level of 
inhibition (1 log.u.) detected in infective virus production. 
Likewise, LG transiently inhibited positive strand viral RNA 
synthesis, from 2 to 3 h.p.i., when total and extracellular viruses 
were analyzed (Figure 5B). At 8 h.p.i., the amount of intracellular 
FMDV RNA was not affected by LG, although extracellular 
virus was significantly reduced, which might reflect a decrease 
of infective virus release in the presence of LG. However, as 
shown in Figure 2, a consistent decrease of at least 1 log.u. 
was observed in the total virus production of two FMDV 
serotypes in cells infected at 24  h.p.i, and at three different 
M.O.I.s, supporting the inhibitory effect of LG at late times 
in FMDV infection.
The effect of time of addition of LG in FMDV infection 
revealed that virus productivity was blocked when LG was 
added up to 7  h.p.i. (Figure 5C), indicating that the step 
inhibited by the drug was late in infection (considering that 
the FMDV cycle is completed in about 8–10 h). With a M.O.I. 
of 0.1 pfu/cell, it is expected that two successive virus cycles 
have occurred at 24  h.p.i. The results in Figure 5C (“low 
M.O.I.”) are consistent with this model showing a plateau in 
virus titers from 8 to 15  h.p.i. (when the second virus round 
is inhibited by LG additions), with the total virus productivity 
recovered when LG was added at 20–24  h.p.i. A similar result 
was reported for the inhibitory action of LG on ASFV infection 
in Vero cells (Hurtado et al., 2008); in this case, virus production 
was inhibited when LG was added up to 5  h.p.i. and the 
maximum virus titer was observed from 15  h.p.i., involving 
the viral DNA replication as the LG-sensitive step in virus 
inhibition. As shown in Figure 5C (“high M.O.I.”), when higher 
M.O.I.s (1 or 5 pfu/cell) were used, most cells resulted initially 
FMDV-infected leading to a single round of infection.
Effect of Esters of Gallic Acid Other Than 
Lauryl Gallate
To determine whether the inhibition of virus infection was 
also observed with esters of gallic acid other than LG, the 
effect of gallic acid (G) and its esters, propyl gallate (PG), 
octyl gallate (OG) (Uozaki et  al., 2007; Yamasaki et  al., 2007), 
and LG, was analyzed in FMDV-infected BHK21 cells. In this 
experiment, ASFV-infected Vero cells were also included. As 
represented in Figure 6, LG was the only compound that 
inhibited FMDV infection, reducing virus yield by up to 2 
log.u, in a range of concentrations (10–30  μM) that still 
maintained cell viability. Neither G nor PG inhibited FMDV 
growth at non-toxic concentrations (up to 100  μM) while OG 
reduced virus yields by 2 log.u. at 100  μM, an effect that 
could be  due, at least in part, to the cell toxicity exerted by 
this OG concentration. This result contrasts with the inhibitory 
effect of OG observed in ASFV (Figure 6), supporting that 
different viruses can show distinct sensitivities to an antiviral 
targeted against cellular functions, likely depending on their 
requirement on the affected cell function.
“In vivo” Model for Foot and Mouth 
Disease Virus Inhibition by Lauryl Gallate
C57 mice were chosen for in vivo studies, as this mouse strain 
is clinically susceptible for FMDV infection (Salguero et  al., 
2005). A preliminary assay for LG toxicity in C57 mice revealed 
non-toxic working concentrations of up to 200  mg/kg 
administered twice daily for 5 consecutive days (data not 
shown). We next evaluated the protective efficacy of LG against 
intraperitoneal challenge of FMDV C-S8 isolate in these mice 
(n  =  10 per group). A dose of 100  mg/kg or 200  mg/kg of 
LG was administered intraperitoneally once daily for 3 (group 
0) or 4 (group −1) consecutive days. Mice were challenged 
with 1,000 pfu of FMDV C-S8 following 1  h (group 0) or 
24  h (group −1) after administration of LG and animals were 
monitored daily for survival rate and clinical score. As reported, 
FMDV produced a limited mortality in C57 mice, with a 
A B
FIGURE 6 | Specificity of the inhibition exerted by LG on FMDV infection. Vero cell monolayers for ASFV or BHK21 for FMDV were incubated for 1 h with G, PG, 
OG, or LG at the indicated concentrations (0–1,000 μM) and then infected with ASFV Ba71V strain or FMDV C-S8 strain in medium containing the same gallate 
esters concentrations. Total virus produced at 24 h.p.i. was titrated by plaque assay on BHK21 (FMDV) or Vero (ASFV) cell monolayers in duplicate samples and 
represented as virus yield (%).
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A
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FIGURE 7 | In vivo model for FMDV inhibition by LG. (A) Survival curves of C57 mice (n = 10) injected i.p. with a dose of 100 mg/kg or 200 mg/kg of LG 
once daily for 3 (group 0) or 4 (group −1) consecutive days. Mice were challenged with 1,000 pfu of FMDV C-S8 following 1 h (groups 0) or 24 h (group −1) 
after administration of LG, and were monitored daily for survival rate and clinical score. (B) RNA quantification. At day 2 p.i., three mice from the two 
groups that were inoculated or not, 24 h previous to infection (−1) with 100 mg/ml of LG, were bled and euthanized. RNA was extracted from blood, 
spleen, thymus, heart, and lung and quantified by RT-qPCR. Statistically significant differences in the number of VRC (viral RNA copies) per ml of blood or 
per mg of tissue between control and LG-treated animals are indicated by asterisks (Student’s t-test, *p < 0.05). Detection limit is indicated as a 
discontinuous line.
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survival rate of 40% in LG-untreated virus-infected controls 
(Figure 7A). Simultaneous inoculation of LG and FMDV 
conferred no protection (group 0), while inoculation of LG 
24  h prior to viral challenge (group −1) increased survival 
rate to 70% at LG doses of 100 mg/kg and 200 mg/kg. Although 
both doses conferred similar protection, mice treated with 
200  mg/kg showed lower weights than those treated with 
100  mg/kg dose.
Next, we  studied whether LG treatment reduced the virus 
load upon mice infection. To this end, a new experiment was 
performed using the protocol (−1), that is, LG injection 24  h 
previous to infection, with a dose of 100  mg/ml of LG 
administered intraperitoneally for 4 consecutive days. Animals 
were bled and euthanized for further dissection at day 2 p.i. 
Total (intracellular and extracellular) virus RNA was extracted 
from blood, spleen, lung, heart, and thymus samples. FMDV 
cDNA was synthesized using reverse transcriptase, and qPCR 
was performed. As shown in Figure 7B, a significant reduction 
of viral RNA copies (VRC) was found in all samples from 
FMDV-infected C57 mice that had received one daily dose of 
LG (100  mg/kg) starting 24  h before virus inoculation.
Overall, these results support that LG can also exert an in 
vivo antiviral effect, in a mouse model, reducing FMDV mortality 
and viral load in C57 mice when administered 24  h previous 
to infection and during the infection process.
Our results provide further characterization of the antiviral 
effect in cultured cells of the inexpensive drugs VPA and LG 
against a highly relevant animal virus such as ASFV that is 
quickly spreading in regions of Europe and Asia. The results 
also extend the antiviral potential of LG to FMDV and SVDV 
causing vesicular diseases in animals. LG, but not other esters 
of gallic acid, can significantly reduce the FMDV growth in 
cultured cells by inhibiting a late step in FMDV infection. 
Interestingly, LG also reduced the mice mortality upon infection 
with FMDV, which causes an economically devastating livestock 
disease. To our knowledge, this is one of the first descriptions 
of a cell-targeted compound with antiviral effect in vivo against 
FMDV with potential for cost-affordable antiviral intervention.
These findings reinforce the interest of testing the effect of 
these compounds in natural hosts as a first line of disease 
defense in case of outbreaks and as a vaccine complement to 
minimize the gap in antibody-mediated protection evoked by 
FMD vaccines.
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